Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis

<p>Duration of PFS in the patient subgroup with MET amplification</p>

Na minha lista:
Detalhes bibliográficos
Autor principal: Chong Kin Liam (15331321) (author)
Outros Autores: Azura Rozila Ahmad (15331324) (author), Te-Chun Hsia (15331327) (author), Jianying Zhou (15331330) (author), Dong-Wan Kim (15036467) (author), Ross Andrew Soo (15331333) (author), Ying Cheng (15331336) (author), Shun Lu (15331339) (author), Sang Won Shin (15331342) (author), James Chih-Hsin Yang (15048002) (author), Yiping Zhang (15331345) (author), Jun Zhao (11571833) (author), Karin Berghoff (15331348) (author), Rolf Bruns (15331351) (author), Andreas Johne (15331354) (author), Yi-Long Wu (11678896) (author)
Publicado em: 2025
Assuntos:
Cancer
Therapeutic Research and Development
Clinical Research and Trials
Chemotherapy
Clinical Trial Results
Clinical-Stage Research
Drug Resistance
Lung Cancer
Precision Medicine
Small Molecule Agents
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
Seja o primeiro a deixar um comentário!
Você deve entrar na sua conta antes

Registros relacionados